推进结核性脑膜炎的化学治疗:共识观点
本文由全球结核性脑膜炎研究联盟以个人观点形式发表,指出结核性脑膜炎约50%患者死亡或残疾、每年约78 200名成人死亡,现有抗菌治疗沿用肺结核方案而忽视肺脑药物分布差异,仅辅助皮质激素有明确获益;迄今试验规模小、把握度不足、异质性大、外推性差且对政策实践影响有限,呼吁通过全球开展的新药和新方案临床试验推进治疗。
要点
- 结核性脑膜炎约50%患者死亡或残疾,每年约78 200名成人死亡。
- 抗菌治疗沿用肺结核方案,忽视肺与脑药物分布的重要差异。
- 炎症反应显著但仅辅助皮质激素有明确获益,需全球协调试验推进。
核心结论
- 结核性脑膜炎现有治疗进展缓慢,需要新的方法,通过全球开展的新药和新方案临床试验来推进治疗并改善这一危及生命感染的结局。
研究设计与样本
- 本文为个人观点(Personal View),由全球结核性脑膜炎研究联盟的研究者撰写。
主要发现
- 结核性脑膜炎在约50%的受影响个体中导致死亡或残疾,每年约造成78 200名成人死亡。
- 抗菌治疗基于用于肺结核的方案,忽视了肺与脑药物分布之间的重要差异。
- 结核性脑膜炎有显著的炎症成分,但只有辅助皮质激素显示出明确获益。
- 针对特定炎症通路的生物制剂的出现,有望开启改善结核性脑膜炎治疗与结局的新时代。
- 迄今结核性脑膜炎试验规模小、把握度不足、异质性大、外推性差,对政策和实践影响甚微。
临床怎么用
- 原文未据此给出推荐。
局限性
- 迄今结核性脑膜炎试验规模小、把握度不足、异质性大、外推性差,对政策和实践影响甚微。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tuberculous meningitis causes death or disability in approximately 50% of affected individuals and kills approximately 78 200 adults every year. Antimicrobial treatment is based on regimens used for pulmonary tuberculosis, which overlooks important differences between lung and brain drug distributions. Tuberculous meningitis has a profound inflammatory component, yet only adjunctive corticosteroids have shown clear benefit. There is an active pipeline of new antitubercular drugs, and the advent of biological agents targeted at specific inflammatory pathways promises a new era of improved tuberculous meningitis treatment and outcomes. Yet, to date, tuberculous meningitis trials have been small, underpowered, heterogeneous, poorly generalisable, and have had little effect on policy and practice. Progress is slow, and a new approach is required. In this Personal View, a global consortium of tuberculous meningitis researchers articulate a coordinated, definitive way ahead via globally conducted clinical trials of novel drugs and regimens to advance treatment and improve outcomes for this life-threatening infection.
引用
- Wasserman S, Donovan J, Kestelyn E, et al. Advancing the chemotherapy of tuberculous meningitis: a consensus view. Lancet Infect Dis. 2024. PMID: 39342951. doi:10.1016/S1473-3099(24)00512-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。